General
Preferred name
LAROPIPRANT
Synonyms
MK-0524 ()
Laropiprant (MK0524) ()
MK 0524 sodium salt ()
Laropiprant+niacin ()
CORDAPTIVE ()
P&D ID
PD012241
CAS
571170-77-9
1046050-73-0
572874-50-1
Tags
available
drug
drug candidate
Drug indication
Dyslipidemia
Arteriosclerosis
Rosacea
Coronary heart disease
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Laropiprant is an orally active prostanoid DP1 receptor antagonist . It inhibits niacin-induced vasodilation . It is also a lower potency agonist of the prostanoid TP receptor . (GtoPdb)
DESCRIPTION Laropiprant is a potent and selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively[1][2][3].
PRICE 105
DESCRIPTION Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM). (TargetMol Bioactive Compound Library)
DESCRIPTION MK 0524 sodium salt is a potent and selective prostaglandin D2 (PGD2) receptor 1 (DP1) antagonist with Ki values to be 0.57 nM and 750 nM for DP1 and DP2 receptors, respectively. (BOC Sciences Bioactive Compounds)
Compound Sets
28
AdooQ Bioactive Compound Library
A11483
Axon Medchem Screening Library
1480
BOC Sciences Bioactive Compounds
mk-0524-sodium-salt-cas-572874-50-1-item-55302
Cayman Chemical Bioactives
10009835
ChEMBL Approved Drugs
CHEMBL426559
ChEMBL Drugs
CHEMBL426559
Concise Guide to Pharmacology 2017/18
3356
Concise Guide to Pharmacology 2019/20
3356
Concise Guide to Pharmacology 2021/22
3356
Concise Guide to Pharmacology 2023/24
3356
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB11629
DrugBank Approved Drugs
DB11629
DrugCentral
4326
DrugCentral Approved Drugs
4326
DrugMAP
DM5FABJ
DM8CEDR
EUbOPEN Chemogenomics Library
EUB0000459
Guide to Pharmacology
3356
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL426559
Mcule NIBR MoA Box Subset
MCULE-7879975928
MedChem Express Bioactive Compound Library
HY-50175
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
laropiprant
TargetMol Bioactive Compound Library
T15712
Withdrawn 2.0
DB11629
ZINC Tool Compounds
ZINC000003961849
External IDs
43
Properties
(calculated by RDKit )
Molecular Weight
435.07
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
4.39
TPSA
76.37
Fraction CSP3
0.29
Chiral centers
1.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
DP/DP1 Receptor
TP Receptor
PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R
DP1 antagonist
Prostaglandin Receptor
Member status
member
MOA
Prostanoid DP (DP1) Antagonists
prostanoid receptor antagonist
Indication
cholesterol
ATC
C10AD52
Toxicity type
NULL
Pathway
GPCR/G protein
Immunology/Inflammation
Recommended Cell Concentration
10 nM
Source data